- Cash and equivalents totaled $27.4 million at quarter-end, with $11 million subject to restrictions.
- Consumables and software revenue grew 16% year-over-year in Q2 and represented 73% of total product revenue, up from 55% last year.
- Flowcell sales increased 17% year-over-year to 7,233 units, indicating strong utilization growth.
- Installed base of optical genome mapping systems was 378, a 4% increase from 363 systems a year ago, with a net decrease of 1 system in the quarter.
- Non-GAAP gross margin improved significantly to 52% from 35% a year ago, driven by cost reductions and manufacturing improvements.
- Non-GAAP operating expenses decreased 53% year-over-year to $8.8 million, reflecting substantial cost-cutting and headcount reduction.
- Total revenue for Q2 2025 was $6.7 million, down 13% year-over-year, or 5% when excluding $700,000 from discontinued services.
Related items and other data are not available for this feed item.
Dafinchi